# Tribun Heallth

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tribun-heallth

- Industry: Software
- Headquarters: Paris, France
- Website: www.tribun.health
- Total disclosed funding: $23M
- Latest round: Series B (Feb 21, 2023)
- Investors on record: 4

## About

Based in Paris, France, and founded in 2016, Tribun Health SAS is engaged in providing solutions to enhance the healthcare and drug development industries. In September 2023, Tribun Heallth SAS raised EUR 15 million in series B funding led by Bpifrance, with participation from LBO France, Owkin, Inc., and Vivalto Santé SAS. Other unspecified investors also participated in the round. As of September 2023, the company has served more than 200 diagnostic and pharmaceutical laboratories and is led by its CEO Jean-François Pomerol.


Tribun Health SAS's product, CaloPix, serves as a state-of-the-art platform for digital pathology, enabling healthcare professionals to make precise clinical decisions. Additionally, the company provides a range of AI applications and services tailored for diagnostics, pharmaceutical research, translational research, and clinical trials. EyeDo, another offering, caters to pharmaceutical research, further enhancing drug development processes. The company's client base includes Cerba, McGill University, Aurigen, Sanofi, and Merck.

The company plans to use the series B funding to further develop and commercialize its product offerings and expand its business reach in North America and Europe.

## Funding rounds

- Series B, Feb 21, 2023, $23M — LBO France, Bpifrance, Vivalto Santé SAS, Owkin, Inc.

## Investors

- LBO France (https://capitalatlas.ai/funds/lbo-france) — Series B
- Bpifrance — Series B
- Vivalto Santé SAS — Series B
- Owkin, Inc. — Series B